Abstract
Heparin-induced thrombocytopenia represents a serious side effect of heparin therapy. Immune-mediated platelet activation results in thrombocytopenia, endothelial thrombin release and development of thrombosis, mainly venous. We report the case of a man with a history of coronary artery disease and recent stent implantation. This patient developed severe heparin-induced thrombocytopenia type II after low molecular weight heparin administration because of unstable angina which occurred two months after stent implantation. The patient was treated with a new anticoagulant regimen, fondaparinux sodium. There were no complications and platelet counts were restored to normal levels.
MeSH terms
-
Angina, Unstable / physiopathology
-
Angina, Unstable / therapy*
-
Angioplasty, Balloon, Coronary / methods*
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects*
-
Blood Vessel Prosthesis Implantation / instrumentation*
-
Electrocardiography
-
Enoxaparin / administration & dosage
-
Enoxaparin / adverse effects*
-
Follow-Up Studies
-
Fondaparinux
-
Humans
-
Injections, Intravenous
-
Injections, Subcutaneous
-
Male
-
Middle Aged
-
Platelet Activation / drug effects
-
Platelet Count
-
Polysaccharides / administration & dosage
-
Polysaccharides / therapeutic use
-
Stents*
-
Thrombocytopenia / blood
-
Thrombocytopenia / chemically induced*
-
Thrombocytopenia / drug therapy
Substances
-
Anticoagulants
-
Enoxaparin
-
Polysaccharides
-
Fondaparinux